Advanced search    

Search: authors:"Hiroyuki Hanai"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Janssen Pharmaceutical KK and Ajinomoto Pharmaceuticals Co. Ltd and has received fees for lectures from Mitsubishi Tanabe Pharma Corporation. Hiroyuki Hanai has nothing to disclose. Toshifumi Hibi has

An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn’s disease

Yoh Ishiguro 3 Satoshi Tanida 4 Sakiko Hiraoka 1 Keiichi Mitsuyama 2 Shunji Ishihara Shinji Tanaka Michiro Otaka Taro Osada Takashi Kagaya Yasuo Suzuki Hiroshi Nakase Hiroyuki Hanai Kenji Watanabe

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Background Adalimumab is a fully human, monoclonal antibody against tumor necrosis factor that is approved in Western countries for the treatment of moderately to severely active ulcerative colitis (UC). Methods This 52-week, phase 2/3, randomized, double-blind study evaluated adalimumab for induction and maintenance treatment in 273 anti-TNF–naive Japanese patients with UC who ...